Unspecified Butorphanol

Verify with FDA CVM →

11 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
3
Deaths Reported
2730.0%
Death Rate

Active Ingredients

Unspecified Butorphanol

Administration Routes

IntravenousUnknownIntramuscular

Species Affected

Dog 8
Cat 3

Most Affected Breeds

Deutsche Dogge, Great Dane 3
Domestic Shorthair 2
Cat (other) 1
Retriever (unspecified) 1
Spitz - American Eskimo Dog 1
Siberian Husky 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Bulldog - American 1

Most Reported Reactions

Unable to walk 3
Seizure NOS 2
Abnormal movement NOS 2
Depressed reflexes 2
Hyperactivity 2
Proprioception deficit 2
Urinary tract infection 2
Myelopathy NOS 2
Haematuria 2
Underdose 2
Panting 2
Lack of efficacy - NOS 1

Outcome Breakdown

Recovered/Normal
4 (36.4%)
Ongoing
3 (27.3%)
Euthanized
2 (18.2%)
Died
1 (9.1%)
Outcome Unknown
1 (9.1%)

Data Summary

Metric Value
Total adverse event reports 11
Reports involving death 3
Case-fatality rate (reported events) 2730.0%
Distinct species in reports 2
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Unspecified Butorphanol Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 11 adverse event reports referencing Unspecified Butorphanol, including 3 reports in which the animal died — a 2730.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Unspecified Butorphanol. Reported administration routes include Intravenous, Unknown, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Unspecified Butorphanol reports are Dog (8 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Deutsche Dogge, Great Dane (3), Domestic Shorthair (2), Cat (other) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Unspecified Butorphanol are Unable to walk (3), Seizure NOS (2), Abnormal movement NOS (2), Depressed reflexes (2). Of the 11 reports with a coded outcome, Recovered/Normal is the leading category at 36.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Unspecified Butorphanol.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial